Natera, Inc.
General ticker "NTRA" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $30.1B (TTM average)
Natera, Inc. follows the US Stock Market performance with the rate: 51.8%.
Estimated limits based on current volatility of 2.6%: low 385.54$, high 406.09$
Factors to consider:
- Total employees count: 6140 (+38.5%) as of 2025
- US accounted for 98.2% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Operational and conduct risks, Market competition, Litigation risks, Cybersecurity threats, Regulatory and compliance
- Current price 31.1% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [168.20$, 300.18$]
- 2026-12-31 to 2027-12-31 estimated range: [139.01$, 258.20$]
Financial Metrics affecting the NTRA estimates:
- Negative: with PPE of -152.3 at the end of fiscal year the price was very high
- Negative: Operating cash flow per share per price, % of 0.68 <= 2.37
- Positive: -13.52 < Operating profit margin, % of -11.85
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: -16.84 < Industry operating profit margin (median), % of -16.21
- Negative: 0.12 < Industry inventory ratio change (median), % of 0.16
- Positive: Inventory ratio change, % of 0.40 <= 0.41
- Positive: Interest expense per share per price, % of 0.01 <= 0.07
- Positive: -1.23 < Investing cash flow per share per price, % of -0.42
Short-term NTRA quotes
Long-term NTRA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,082.57MM | $1,696.91MM | $2,306.11MM |
| Operating Expenses | $1,528.82MM | $1,919.20MM | $2,616.02MM |
| Operating Income | $-446.25MM | $-222.29MM | $-309.91MM |
| Non-Operating Income | $11.71MM | $32.56MM | $41.82MM |
| Interest Expense | $12.64MM | $10.69MM | $4.07MM |
| R&D Expense | $320.68MM | $404.14MM | $624.11MM |
| Income(Loss) | $-434.53MM | $-189.73MM | $-268.09MM |
| Taxes | $0.27MM | $0.69MM | $-59.93MM |
| Net Income(Loss)* | $-434.80MM | $-190.43MM | $-208.16MM |
| Stockholders Equity | $765.33MM | $1,195.42MM | $1,712.41MM |
| Inventory | $40.76MM | $44.74MM | $68.44MM |
| Assets | $1,441.70MM | $1,660.73MM | $2,398.34MM |
| Operating Cash Flow | $-246.96MM | $135.66MM | $215.30MM |
| Capital expenditure | $39.20MM | $66.42MM | $106.19MM |
| Investing Cash Flow | $168.50MM | $137.62MM | $-132.21MM |
| Financing Cash Flow | $254.46MM | $30.20MM | $47.46MM |
| Earnings Per Share** | $-3.78 | $-1.53 | $-1.52 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.